Blog

FSD Pharma Quebec Partner Cannara Biotech Closes Over $17.6 Million Equity Financing to Begin Build Out of First Phase of 625,000 Square Foot Indoor Grow

TORONTO, July 24, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) (OTC:FSDDF) is pleased to announce its strategic partner Cannara Biotech Inc. (“Cannara”) closed $17.66 million common share equity financing.

FSD is a significant Cannara shareholder and has applied for a second site license at the Cannara facility. FSD made an investment of $1 million dollars in this round of financing. First Republic Capital Corp. was the sole broker for the offering, the proceeds of which will support the first Phase build-out at Cannara’s Farnham, Quebec facility, as well as fund product development. Continue Reading

FSD Pharma Appoints a Special Committee of the Board for Mergers and Acquisitions and Interim Chief Financial Officer

TORONTO, July 23, 2018 /CNW/ – Thomas Fairfull, President and Chief Executive Officer of FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) (OTC:FSDDF), is pleased to announce the appointment of a Special Committee of the Board of Directors to focus on Merger and Acquisition Opportunities and also the appointment of Donal Carroll as interim Chief Financial Officer. Continue Reading

FSD Pharma Stock Appears to Have Enormous Potential

FSD Pharma Inc.’s (CSE:HUGE) mission is to transform a former Kraft food plant into the largest hydroponic indoor cannabis facility in the world

SmallCapPower | July 20, 2018: FSD Pharma Inc. (CSE:HUGE) is a cannabis company that holds a license to cultivate cannabis under Access to Cannabis for Medical Purposes Regulations (ACMPR) through its subsidiary FV Pharma Inc. Headquartered at the former Kraft plant in Cobourg, Ontario, the Company originally received its cultivation license on October 13, 2017. FSD Pharma Inc.’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. The Company aims to target all aspects of the cannabis industry – cultivation, processing, manufacturing, extracts and research and development. Continue Reading

FSD Pharma Enters Into Saskatchewan Wholesale Supply MOU of up to 5,000 Kilograms With High Tide Ventures

TORONTOJuly 19, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma”) (CSE:HUGE) (OTC:FSDDF) today announced that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) has entered into a non-binding memorandum of understanding (“MOU”) with High Tide Ventures Inc. (“High Tide”) dated July 18, 2018 to supply the Saskatchewanmarket on a wholesale basis with up to 5,000 kilograms of cannabis products over the next year when available. FSD Pharma is working together with Auxly (formerly Cannabis Wheaton Income Corp.) (TSX.V:XLY) to achieve its mission to develop the largest hydroponic indoor cannabis cultivation facility in Cobourg, Ontario, Canada.

Continue Reading

FSD Pharma Inc. announces acquisition to expand in Newfoundland for production and sales

TORONTOJuly 12, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) (OTC: FSDDF) is pleased to announce a binding agreement to purchase 51% of Atlantic Island Cannabis Inc. (to be renamed FSD Atlantic Pharma Inc.) effective July 4, 2018. The agreement involves a strategic investment of $40 million to drive production and sales of legal cannabis in the province of Newfoundland. In the first phase of the project, an indoor high quality 45,000 square foot cannabis production facility will be set up in FreshwaterCarbonear, Newfoundland. Continue Reading

FSD Pharma Announces Collaboration and Profit Sharing Agreement with Canntab for Production and Market of Oral Dose Delivery Platforms

TORONTOJuly 10, 2018 /CNW/ – FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (“FSD Pharma“), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI“) with Canntab Therapeutics Limited (CSE: PILL) (“Canntab“), a leader in the rapidly growing cannabis pill market. Under the terms of the LOI, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the “License“), and will provide Canntab with space at its 620,000 square foot facility (the “FSD Facility“), which is located just one hour east of Toronto in Cobourg, Ontario (the “Transaction“). Continue Reading

FSD Pharma Breaks All-Time Monthly Stock Volume Trading Record

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTO, July 5, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that in the one month period of trading between May 29, 2018 and June 28, 2018, the company traded exactly 869,232,894 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). Continue Reading

FSD Pharma Inc. announces $55 million dollar indoor cannabis grow partnership expansion at its Cobourg facility

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJuly 3, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) is pleased to provide an update on the progress of the joint venture between its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma) and Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly”). Continue Reading

FSD Pharma Breaks All-Time Weekly Stock Volume Trading Record

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 25, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that in the last 5 consecutive days of trading, the company traded exactly 269,961,050 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). Continue Reading